Monograph
A02BX05 - Bismuth Subcitrate |
Propably not porphyrinogenic |
PNP |
Rationale
Bismuth citrate is an inorganic salt and it is not metabolized. No porphyrinogenic effects are expected.
Chemical description
Bismuth subcitrate (bismuth tripotassium dicitrate) is a salt of bismuth, potassium and citric acid (Drug Bank).
Therapeutic characteristics
Bismuth citrate is used in the treatment of gastroduodenal disorders and may be used in combination with other drugs for eradication of Helicobacter pylori.
It is administrated orally.
Metabolism and pharmacokinetics
Bismuth is widely distributed throughout the entire body, and is eliminated through urinary and biliary routes. Half-life of 5 days suggests tissue accumulation (FDA).
No studies of CYP interaction potential is identified, but this is not expected.
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | DrugBank. Bismuth subcitrate.
|
|
| * | Government bodies | |
| 2. | U.S. Food and Drug Administration (FDA). Label information PYLERA. (Revised: 01.2018).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Poland
Serbia© NAPOS 2024